Affordability of commonly prescribed antibiotics in a large tertiary teaching hospital in Ethiopia: a challenge for the national drug policy objective.

Publisher: Biomed Central Country of Publication: England NLM ID: 101462768 Publication Model: Electronic Cited Medium: Internet ISSN: 1756-0500 (Electronic) Linking ISSN: 17560500 NLM ISO Abbreviation: BMC Res Notes Subsets: MEDLINE

Original Publication: London : Biomed Central, 2008.

Anti-Bacterial Agents*/economics ; Anti-Bacterial Agents*/supply & distribution ; Drugs, Essential*/economics ; Drugs, Essential*/supply & distribution ; Health Policy* ; Pharmacies*/economics ; Pharmacies*/supply & distribution; Hospitals, Teaching/*statistics & numerical data ; Tertiary Care Centers/*statistics & numerical data; Ethiopia ; Humans ; Private Sector/statistics & numerical data ; Public Sector/statistics & numerical data

Objective: In national drug policies of many countries, ensuring availability and affordability of essential medicines is indicated among the major policy objectives. To achieve the objectives, countries with low and middle income compile such medicines into NEMLs. This study aims to determine availability and affordability of commonly prescribed antibiotics at a tertiary hospital in Ethiopia by assessing (in private and public pharmacies) 13 antibiotics constituting DU90% at the hospital.
Results: Availability of the antibiotics in the private and public pharmacies was 92.3% and 98.5%, respectively. Average MPRs for the antibiotics were 4.1 and 2.7, respectively, in the private and public pharmacies. The days' wages (in median prices) ranged from 0.2 for treating acute diarrhea with doxycycline to 415.8 for treating HAP in public pharmacies. Costs of a single day treatment with antibiotics purchased from the public pharmacies ranged from USD 0.1 for acute diarrhea to USD 29.7 for HAP. For the private pharmacies, the range was from USD 0.1 for toxoplasmosis to USD 54.9 for HAP. This study showed that treatments of commonly diagnosed infectious conditions at TASH remain unaffordable according to the WHO/HAI criteria.

Lancet. 2006 Oct 14;368(9544):1357-64. (PMID: 17046468)
Neuroepidemiology. 2007;28(3):169-74. (PMID: 17536229)
Lancet. 2009 Jan 17;373(9659):240-9. (PMID: 19042012)
Pharm World Sci. 2009 Apr;31(2):209-15. (PMID: 19263235)
Bull World Health Organ. 2009 Feb;87(2):139-42. (PMID: 19274366)
Trop Med Int Health. 2009 Nov;14(11):1394-400. (PMID: 19754520)
Orbit. 2009;28(2-3):147-52. (PMID: 19839899)
Asia Pac J Public Health. 2010 Jul;22(3 Suppl):96S-102S. (PMID: 20566540)
Am J Trop Med Hyg. 2010 Sep;83(3):571-4. (PMID: 20810822)
PLoS Med. 2010 Aug 31;7(8):null. (PMID: 20824175)
Bull World Health Organ. 2011 Jun 1;89(6):412-21. (PMID: 21673857)
Croat Med J. 2012 Apr;53(2):173-84. (PMID: 22522996)
Value Health. 2012 Jul-Aug;15(5):664-73. (PMID: 22867775)
BMC Health Serv Res. 2013 May 07;13:170. (PMID: 23647871)
BMC Public Health. 2014 Aug 08;14:817. (PMID: 25103467)
Afr J Prim Health Care Fam Med. 2014 Jun 24;6(1):E1-6. (PMID: 26245401)
Drug Des Devel Ther. 2015 Aug 10;9:4551-7. (PMID: 26309400)
BMC Health Serv Res. 2015 Aug 27;15:345. (PMID: 26310243)
BMC Pediatr. 2016 Mar 15;16:40. (PMID: 26979737)
Ethiop J Health Sci. 2016 May;26(3):259-76. (PMID: 27358547)
PLoS One. 2017 Mar 6;12(3):e0173290. (PMID: 28264021)
Asia Pac J Public Health. 2017 May;29(4):268-277. (PMID: 28397532)
PLoS One. 2017 Apr 18;12(4):e0175399. (PMID: 28419126)
Clinicoecon Outcomes Res. 2017 Jun 14;9:353-359. (PMID: 28652789)
Antimicrob Resist Infect Control. 2017 Jun 26;6:70. (PMID: 28670450)
J Pharm Policy Pract. 2017 Nov 15;10:35. (PMID: 29163976)
BMC Health Serv Res. 2018 May 3;18(1):326. (PMID: 29724214)

Keywords: Affordability; Antibiotics; Ethiopia; Policy; TASH

0 (Anti-Bacterial Agents)
0 (Drugs, Essential)

Date Created: 20181228 Date Completed: 20190410 Latest Revision: 20200225

20240829

PMC6307120

10.1186/s13104-018-4021-2

30587231